Silence Therapeutics Raising $8.8M To Send RNAi Drug To Phase IIa
With a deeply discounted subscription and open share offering, the U.K.'s RNAi specialist, Silence Therapeutics, hopes to reach proof of concept with its lead product candidate.
With a deeply discounted subscription and open share offering, the U.K.'s RNAi specialist, Silence Therapeutics, hopes to reach proof of concept with its lead product candidate.